Not available
Quote | OncoMed Pharmaceuticals Inc. (NASDAQ:OMED)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $0.89 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | OncoMed Pharmaceuticals Inc. (NASDAQ:OMED)
Quick Take Nkarta ( NKTX ) intends to raise $150 million in an IPO of its common stock, according to an amended registration statement . The company is advancing a pipeline of drug candidates for the treatment of blood and other cancer indications. NKTX is still at preclinical stage of ...
Notice of Preliminary Results THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Mereo...
Message Board Posts | OncoMed Pharmaceuticals Inc. (NASDAQ:OMED)
Subject | By | Source | When |
---|---|---|---|
Wheres $1.65? | The-REAL-KING-of-pennies | investorshub | 05/01/2023 2:02:51 PM |
$MONI already ran past the .01 mark which | The-REAL-KING-of-pennies | investorshub | 04/29/2023 12:21:36 PM |
watch and learn...moni sinks....mreo rises! | TrendTrade2016 | investorshub | 04/29/2023 12:20:01 PM |
Like I said. Its hard to even | The-REAL-KING-of-pennies | investorshub | 04/29/2023 12:16:19 PM |
.005-.02 - $MONI $1- $1.30$ MREO Lol Again, | The-REAL-KING-of-pennies | investorshub | 04/29/2023 12:09:45 PM |
News, Short Squeeze, Breakout and More Instantly...
OncoMed Pharmaceuticals Inc. Company Name:
OMED Stock Symbol:
NASDAQ Market:
OncoMed Pharmaceuticals Inc. Website:
Notice of Preliminary Results THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Mereo...
LONDON, April 18, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces today that stockholders of OncoMed (NASDAQ: OMED) have approved the transactions contemplated by the merger agreement da...
REDWOOD CITY, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (“OncoMed”) (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that its board of directors declar...